| pubmed-article:16287993 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16287993 | lifeskim:mentions | umls-concept:C0006826 | lld:lifeskim |
| pubmed-article:16287993 | lifeskim:mentions | umls-concept:C0332307 | lld:lifeskim |
| pubmed-article:16287993 | lifeskim:mentions | umls-concept:C0140079 | lld:lifeskim |
| pubmed-article:16287993 | lifeskim:mentions | umls-concept:C0302350 | lld:lifeskim |
| pubmed-article:16287993 | lifeskim:mentions | umls-concept:C1521840 | lld:lifeskim |
| pubmed-article:16287993 | pubmed:issue | 22 | lld:pubmed |
| pubmed-article:16287993 | pubmed:dateCreated | 2005-11-18 | lld:pubmed |
| pubmed-article:16287993 | pubmed:abstractText | Data from experimental model systems and population studies have implicated type I insulin-like growth factor receptor (IGF1R) signaling in many different human cancers. Drugs to disrupt IGF1R function have been developed and are now entering clinical trial. This brief review will identify key areas to consider as these clinical trials move forward. | lld:pubmed |
| pubmed-article:16287993 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16287993 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16287993 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16287993 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16287993 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16287993 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:16287993 | pubmed:issn | 0008-5472 | lld:pubmed |
| pubmed-article:16287993 | pubmed:author | pubmed-author:YeeDouglasD | lld:pubmed |
| pubmed-article:16287993 | pubmed:author | pubmed-author:MillerBradley... | lld:pubmed |
| pubmed-article:16287993 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16287993 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:16287993 | pubmed:volume | 65 | lld:pubmed |
| pubmed-article:16287993 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16287993 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16287993 | pubmed:pagination | 10123-7 | lld:pubmed |
| pubmed-article:16287993 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:16287993 | pubmed:meshHeading | pubmed-meshheading:16287993... | lld:pubmed |
| pubmed-article:16287993 | pubmed:meshHeading | pubmed-meshheading:16287993... | lld:pubmed |
| pubmed-article:16287993 | pubmed:meshHeading | pubmed-meshheading:16287993... | lld:pubmed |
| pubmed-article:16287993 | pubmed:meshHeading | pubmed-meshheading:16287993... | lld:pubmed |
| pubmed-article:16287993 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:16287993 | pubmed:articleTitle | Type I insulin-like growth factor receptor as a therapeutic target in cancer. | lld:pubmed |
| pubmed-article:16287993 | pubmed:affiliation | Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota 55455, USA. | lld:pubmed |
| pubmed-article:16287993 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16287993 | pubmed:publicationType | Review | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16287993 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16287993 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16287993 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16287993 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16287993 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16287993 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16287993 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16287993 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16287993 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16287993 | lld:pubmed |
